Neogen Corporation Increase (Decrease) in Interest Payable, Net
Neogen Corporation (NEOG) reported Increase (Decrease) in Interest Payable, Net of -$7.60 million for the 9-month period ending 2026-02-28, per its 10-Q filed 2026-04-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2026-04-09
- Neogen Corporation increase (decrease) in interest payable, net for the quarter ending 2026-02-28 was -$7.54M.
- Neogen Corporation increase (decrease) in interest payable, net for the quarter ending 2025-11-30 was $7.46M, a 1.01% decline year-over-year.
- Neogen Corporation increase (decrease) in interest payable, net for the quarter ending 2025-08-31 was -$7.52M.
- Neogen Corporation increase (decrease) in interest payable, net for the quarter ending 2025-05-31 was $7.59M, a 0.61% increase year-over-year.
- Neogen Corporation increase (decrease) in interest payable, net for fiscal 2025 was $93.00K.
- Neogen Corporation increase (decrease) in interest payable, net for fiscal 2024 was -$164.00K, a 104.05% decline from fiscal 2023.
- Neogen Corporation increase (decrease) in interest payable, net for fiscal 2023 was $4.05M.
- Neogen Corporation increase (decrease) in interest payable, net for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 9 month as first filed | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|---|
| 2026-02-28 | -$7.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-09 | -$79.00K derived: sum of 2 quarters · filed 2026-04-09 | -$7.60M 10-Q · filed 2026-04-09 | -$7.00K derived: sum of 4 quarters · filed 2026-04-09 | |
| 2025-11-30 | $7.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-01-08 | -$60.00K 10-Q · filed 2026-01-08 | $7.53M derived: sum of 3 quarters · filed 2026-01-08 | -$73.00K derived: sum of 4 quarters · filed 2026-04-09 | |
| 2025-08-31 | -$7.52M 10-Q · filed 2025-10-09 | $72.00K derived: sum of 2 quarters · filed 2025-10-09 | -$7.53M derived: sum of 3 quarters · filed 2026-04-09 | $3.00K derived: sum of 4 quarters · filed 2026-04-09 | |
| 2025-05-31 | $7.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | -$13.00K derived: sum of 2 quarters · filed 2026-04-09 | $7.52M derived: sum of 3 quarters · filed 2026-04-09 | $93.00K 10-K · filed 2025-07-30 | |
| 2025-02-28 | -$7.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-09 | -$69.00K derived: sum of 2 quarters · filed 2026-04-09 | -$7.50M 10-Q · filed 2026-04-09 | -$7.55M 10-Q · filed 2025-04-09 | $47.00K derived: sum of 4 quarters · filed 2026-04-09 |
| 2024-11-30 | $7.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-01-08 | $106.00K 10-Q · filed 2026-01-08 | $7.65M derived: sum of 3 quarters · filed 2026-01-08 | $106.00K derived: sum of 4 quarters · filed 2026-01-08 | |
| 2024-08-31 | -$7.43M 10-Q · filed 2025-10-09 | $116.00K derived: sum of 2 quarters · filed 2025-10-09 | -$7.43M derived: sum of 3 quarters · filed 2025-10-09 | $116.00K derived: sum of 4 quarters · filed 2025-10-09 | |
| 2024-05-31 | $7.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | $0.00 derived: sum of 2 quarters · filed 2025-07-30 | $7.55M derived: sum of 3 quarters · filed 2025-07-30 | -$164.00K 10-K · filed 2025-07-30 | |
| 2024-02-29 | -$7.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-09 | $0.00 derived: sum of 2 quarters · filed 2025-04-09 | -$7.71M 10-Q · filed 2025-04-09 | -$7.10M derived: sum of 4 quarters · filed 2025-07-30 | |
| 2023-11-30 | $7.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-15 | -$164.00K 10-Q · filed 2025-01-15 | $450.00K derived: sum of 3 quarters · filed 2025-07-30 | -$10.09M derived: sum of 4 quarters · filed 2025-07-30 | |
| 2023-08-31 | -$7.71M 10-Q · filed 2024-10-10 | -$7.10M derived: sum of 2 quarters · filed 2025-07-30 | -$17.63M derived: sum of 3 quarters · filed 2025-07-30 | -$3.66M derived: sum of 4 quarters · filed 2025-07-30 | |
| 2023-05-31 | $614.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | -$9.92M derived: sum of 2 quarters · filed 2025-07-30 | $4.05M derived: sum of 3 quarters · filed 2025-07-30 | $4.05M 10-K · filed 2025-07-30 | |
| 2023-02-28 | -$10.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-04-09 | $3.44M derived: sum of 2 quarters · filed 2024-04-09 | $3.44M 10-Q · filed 2024-04-09 | $3.44M derived: sum of 4 quarters · filed 2024-07-30 | |
| 2022-11-30 | $13.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-01-09 | $13.97M 10-Q · filed 2024-01-09 | $13.97M derived: sum of 3 quarters · filed 2024-07-30 | $13.97M derived: sum of 4 quarters · filed 2024-07-30 | |
| 2022-08-31 | $0.00 10-Q · filed 2023-10-10 | $0.00 derived: sum of 2 quarters · filed 2024-07-30 | $0.00 derived: sum of 3 quarters · filed 2024-07-30 | ||
| 2022-05-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $0.00 derived: sum of 2 quarters · filed 2024-07-30 | $0.00 10-K · filed 2024-07-30 | ||
| 2022-02-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-04-04 | $0.00 10-Q · filed 2023-04-04 | |||
| 2021-11-30 | $0.00 10-Q · filed 2023-01-09 | ||||
| 2021-05-31 | $0.00 10-K · filed 2023-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |